12.07.2015 Views

FA 5 Progress Report WV-INBRE - Joan C. Edwards School of ...

FA 5 Progress Report WV-INBRE - Joan C. Edwards School of ...

FA 5 Progress Report WV-INBRE - Joan C. Edwards School of ...

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Program Director/Principal Investigator (Last, First, Middle): Rankin, Gary O 46and their receptors and have demonstrated that both fibroblast growth factors and their receptorsare expressed by meningioma cells. Further, growth factor message levels are modulated bysteroid hormones. Treatment <strong>of</strong> meningioma cells with antagonists <strong>of</strong> FGF receptors decreasesthe proliferation <strong>of</strong> the cells and the phosphorylation <strong>of</strong> ERK1 and 2. Together, these resultsprovide more evidence that steroid hormones may affect the expression <strong>of</strong> fibroblast growth factors(FGF2 and FGF9) in meningiomas and also that an FGF autocrine loop plays a role in meningiomacell proliferation, partially by signaling through ERK1/2.Of other genes identified to examine in specific aims 1 and2, we have found that the expression <strong>of</strong>the cyclin dependent kinase p27 kip1 (CDKN1B) is modulated in meningioma cells by both theprogesterone antagonist Mifepristone and the histone deacetylase inhibitor butyric acid. Thetranscriptional repressor KLF10 (Krueppel-like factor 10 or TIEG-1) was down regulated by a factor<strong>of</strong> 32 by the estrogen receptor antagonist, ZK164015 in more aggressive lines <strong>of</strong> meningioma,while Mifepristone had no effect. Since PR is typically higher in lower grades <strong>of</strong> meningioma whileER increases in higher grades, we are examining this in cells from lower grade tumors. KLF10expression also was modulated by butyric acid.Although SLC20A2 (GLVR-2, Pit2) was not highlighted in the grant, we found that its expressionwas significantly down regulated by Mifepristone. Expression was also modulated by HDACinhibitor treatment. Little is known about this gene outside <strong>of</strong> its function in the kidney, although ithas been focus <strong>of</strong> gene therapy work as the Gibbon ape leukemia virus receptor 2, and wespeculate that it may be involved in the calcification <strong>of</strong> the tumors.The work <strong>of</strong> one graduate student who graduated during the past year was published during thesummer: Manohar S, Harlow M, Nguyen H, Li J, Hankins GR, Park M, Chromatin modifying protein1A (Chmp1A) <strong>of</strong> the endosomal sorting complex required for transport (ESCRT)-III family activatesataxia-telangiectasia mutated (ATM) for PanC-1 cell growth inhibition. Cell Cycle 10 (15):2529-2539, 2011. Although Dr. Park has left Marshall University and Dr. Travis Salisbury hasreplaced her as the mentor, we are still collaborating on studies on chromatin modifying proteins.Dr. Salisbury’s research on the aryl hydrocarbon receptor complements the grant research giventhe parallels and crosstalk between AHR and steroid receptors.PROTECTION AGAINST RESEARCH RISKSN 1. Will human subjects be involved next year?N 2. Will vertebrate animals be used next year?N 3. Will recombinant DNA experiment(s) be conducted next year?N 4. Are there potential hazards to laboratory workers (carcinogens, pathogens, ionizing radiation, etc.)involved in the proposed research for next year? If yes, identify:N5. Will any <strong>of</strong> the research-risk categories,not involved next year, be involved future years? If yes, identify:PHS 2590 (Rev. 06/09)Continuation Format Page

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!